October 12, 2020
1 min read
Save

Fresenius partners with Livongo for virtual CKD management

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Through Fresenius Medical Care North America’s recently announced partnership with Livongo Health Inc., patients will now be managed utilizing Livongo’s Whole Person for CKD virtual care-coordination services.

According to a press release, Livongo’s health care management solutions have already been implemented for patients with diabetes and hypertension; this partnership marks the first time patients with kidney disease will also have access.

online community
Source: Adobe Stock

The release elaborated on the service, described as an “applied health signals platform,” noting that Livongo uses a “connected ecosystem,” that allows clinicians to tailor health plans to individual patients through access to real-time patient data.

Cellular-connected devices and integration with continuous glucose monitors, access to health coaches and health insights are also included in the service, according to the release.

The expressed goal is to improve health outcomes and reduce costs for members of Fresenius Health Partners.

Glen Tullman, founder and executive chair of the company, further explained in the release.

“Through Livongo’s advanced data science engine and clinically based approach, we can effectively use our proven solutions to empower individuals living with chronic kidney disease,” he said.

Bill Valle

“By adding Livongo to our value-based care services, we can make a positive impact in the lives of people living with kidney disease,” Bill Valle, CEO of Fresenius Medical Care North America, said. “We are excited to add this proven suite of technologies and services as we expand our leadership in renal care management and work to slow the progression of kidney disease.”